Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192284372> ?p ?o ?g. }
- W3192284372 endingPage "5409" @default.
- W3192284372 startingPage "5401" @default.
- W3192284372 abstract "Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity. This study investigated PCV13 impact on serotype-specific pneumococcal carriage prevalence, density, and serotype diversity in PNG infants, who have some of the highest reported rates of pneumococcal carriage and disease in the world.Nasopharyngeal swabs were collected at 1, 4 and 9 months of age from PCV13-vaccinated infants (n = 57) and age-/season-matched, unvaccinated infants (at approximately 1 month, n = 53; 4 months, n = 57; 9 months, n = 52). Serotype-specific pneumococcal carriage density and antimicrobial resistance genes were identified by qPCR and microarray.Pneumococci were present in 89% of swabs, with 60 different serotypes and four non-encapsulated variants detected. Multiple serotype carriage was common (47% of swabs). Vaccine type carriage prevalence was similar between PCV13-vaccinated and unvaccinated infants at 4 and 9 months of age. The prevalence of non-vaccine type carriage was also similar between cohorts, with non-vaccine types present in three-quarters of samples (from both vaccinated and unvaccinated infants) by 4 months of age. The median pneumococcal carriage density was high and similar at each age group (~7.0 log10genome equivalents/mL). PCV13 had no effect on overall pneumococcal carriage density, vaccine type density, non-vaccine type density, or the prevalence of antimicrobial resistance genes.PNG infants experience dense and diverse pneumococcal colonisation with concurrent serotypes from 1 month of age. PCV13 had no impact on pneumococcal carriage density, even for vaccine serotypes. The low prevalence of vaccine serotypes, high pneumococcal carriage density and abundance of non-vaccine serotypes likely contribute to the lack of PCV13 impact on carriage in PNG infants. Indirect effects of the infant PCV programs are likely to be limited in PNG. Alternative vaccines with broader coverage should be considered." @default.
- W3192284372 created "2021-08-16" @default.
- W3192284372 creator A5001055850 @default.
- W3192284372 creator A5011773591 @default.
- W3192284372 creator A5012921982 @default.
- W3192284372 creator A5016095339 @default.
- W3192284372 creator A5017585559 @default.
- W3192284372 creator A5030667842 @default.
- W3192284372 creator A5031072351 @default.
- W3192284372 creator A5037382997 @default.
- W3192284372 creator A5042180606 @default.
- W3192284372 creator A5049164171 @default.
- W3192284372 creator A5051816946 @default.
- W3192284372 creator A5056800052 @default.
- W3192284372 creator A5071514214 @default.
- W3192284372 creator A5075178595 @default.
- W3192284372 creator A5079221956 @default.
- W3192284372 creator A5081604173 @default.
- W3192284372 creator A5087063535 @default.
- W3192284372 date "2021-09-01" @default.
- W3192284372 modified "2023-10-06" @default.
- W3192284372 title "Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants" @default.
- W3192284372 cites W1806265131 @default.
- W3192284372 cites W1954112402 @default.
- W3192284372 cites W1964697646 @default.
- W3192284372 cites W2027329006 @default.
- W3192284372 cites W2098332275 @default.
- W3192284372 cites W2108437815 @default.
- W3192284372 cites W2110005071 @default.
- W3192284372 cites W2136396527 @default.
- W3192284372 cites W2153272057 @default.
- W3192284372 cites W2157583453 @default.
- W3192284372 cites W2164775303 @default.
- W3192284372 cites W2180378587 @default.
- W3192284372 cites W2299345761 @default.
- W3192284372 cites W2516481803 @default.
- W3192284372 cites W2528314448 @default.
- W3192284372 cites W2594878923 @default.
- W3192284372 cites W2606215982 @default.
- W3192284372 cites W2619684722 @default.
- W3192284372 cites W2736852390 @default.
- W3192284372 cites W2740875853 @default.
- W3192284372 cites W2767569096 @default.
- W3192284372 cites W2810449130 @default.
- W3192284372 cites W2899848198 @default.
- W3192284372 cites W2903503946 @default.
- W3192284372 cites W2948191744 @default.
- W3192284372 cites W2955935332 @default.
- W3192284372 cites W2982564879 @default.
- W3192284372 doi "https://doi.org/10.1016/j.vaccine.2021.07.085" @default.
- W3192284372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34384633" @default.
- W3192284372 hasPublicationYear "2021" @default.
- W3192284372 type Work @default.
- W3192284372 sameAs 3192284372 @default.
- W3192284372 citedByCount "8" @default.
- W3192284372 countsByYear W31922843722022 @default.
- W3192284372 countsByYear W31922843722023 @default.
- W3192284372 crossrefType "journal-article" @default.
- W3192284372 hasAuthorship W3192284372A5001055850 @default.
- W3192284372 hasAuthorship W3192284372A5011773591 @default.
- W3192284372 hasAuthorship W3192284372A5012921982 @default.
- W3192284372 hasAuthorship W3192284372A5016095339 @default.
- W3192284372 hasAuthorship W3192284372A5017585559 @default.
- W3192284372 hasAuthorship W3192284372A5030667842 @default.
- W3192284372 hasAuthorship W3192284372A5031072351 @default.
- W3192284372 hasAuthorship W3192284372A5037382997 @default.
- W3192284372 hasAuthorship W3192284372A5042180606 @default.
- W3192284372 hasAuthorship W3192284372A5049164171 @default.
- W3192284372 hasAuthorship W3192284372A5051816946 @default.
- W3192284372 hasAuthorship W3192284372A5056800052 @default.
- W3192284372 hasAuthorship W3192284372A5071514214 @default.
- W3192284372 hasAuthorship W3192284372A5075178595 @default.
- W3192284372 hasAuthorship W3192284372A5079221956 @default.
- W3192284372 hasAuthorship W3192284372A5081604173 @default.
- W3192284372 hasAuthorship W3192284372A5087063535 @default.
- W3192284372 hasBestOaLocation W31922843721 @default.
- W3192284372 hasConcept C10389963 @default.
- W3192284372 hasConcept C142724271 @default.
- W3192284372 hasConcept C159047783 @default.
- W3192284372 hasConcept C187212893 @default.
- W3192284372 hasConcept C22070199 @default.
- W3192284372 hasConcept C2776152631 @default.
- W3192284372 hasConcept C2778866548 @default.
- W3192284372 hasConcept C2781253189 @default.
- W3192284372 hasConcept C32762888 @default.
- W3192284372 hasConcept C501593827 @default.
- W3192284372 hasConcept C71924100 @default.
- W3192284372 hasConcept C86803240 @default.
- W3192284372 hasConcept C89423630 @default.
- W3192284372 hasConcept C94665300 @default.
- W3192284372 hasConceptScore W3192284372C10389963 @default.
- W3192284372 hasConceptScore W3192284372C142724271 @default.
- W3192284372 hasConceptScore W3192284372C159047783 @default.
- W3192284372 hasConceptScore W3192284372C187212893 @default.
- W3192284372 hasConceptScore W3192284372C22070199 @default.
- W3192284372 hasConceptScore W3192284372C2776152631 @default.
- W3192284372 hasConceptScore W3192284372C2778866548 @default.
- W3192284372 hasConceptScore W3192284372C2781253189 @default.
%20introduced%20the%2013-valent%20pneumococcal%20conjugate%20vaccine%20(PCV13)%20in%202014%2C%20with%20administration%20at%201%2C%202%2C%20and%203%20months%20of%20age.%20PCV13%20has%20reduced%20or%20eliminated%20carriage%20of%20vaccine%20types%20in%20populations%20with%20low%20pneumococcal%20carriage%20prevalence%2C%20carriage%20density%20and%20serotype%20diversity.%20This%20study%20investigated%20PCV13%20impact%20on%20serotype-specific%20pneumococcal%20carriage%20prevalence%2C%20density%2C%20and%20serotype%20diversity%20in%20PNG%20infants%2C%20who%20have%20some%20of%20the%20highest%20reported%20rates%20of%20pneumococcal%20carriage%20and%20disease%20in%20the%20world.Nasopharyngeal%20swabs%20were%20collected%20at%201%2C%204%20and%209%20months%20of%20age%20from%20PCV13-vaccinated%20infants%20(n%20%3D%2057)%20and%20age-%2Fseason-matched%2C%20unvaccinated%20infants%20(at%20approximately%201%20month%2C%20n%20%3D%2053%3B%204%20months%2C%20n%20%3D%2057%3B%209%20months%2C%20n%20%3D%2052).%20Serotype-specific%20pneumococcal%20carriage%20density%20and%20antimicrobial%20resistance%20genes%20were%20identified%20by%20qPCR%20and%20microarray.Pneumococci%20were%20present%20in%2089%25%20of%20swabs%2C%20with%2060%20different%20serotypes%20and%20four%20non-encapsulated%20variants%20detected.%20Multiple%20serotype%20carriage%20was%20common%20(47%25%20of%20swabs).%20Vaccine%20type%20carriage%20prevalence%20was%20similar%20between%20PCV13-vaccinated%20and%20unvaccinated%20infants%20at%204%20and%209%20months%20of%20age.%20The%20prevalence%20of%20non-vaccine%20type%20carriage%20was%20also%20similar%20between%20cohorts%2C%20with%20non-vaccine%20types%20present%20in%20three-quarters%20of%20samples%20(from%20both%20vaccinated%20and%20unvaccinated%20infants)%20by%204%20months%20of%20age.%20The%20median%20pneumococcal%20carriage%20density%20was%20high%20and%20similar%20at%20each%20age%20group%20(~7.0%20log10genome%20equivalents%2FmL).%20PCV13%20had%20no%20effect%20on%20overall%20pneumococcal%20carriage%20density%2C%20vaccine%20type%20density%2C%20non-vaccine%20type%20density%2C%20or%20the%20prevalence%20of%20antimicrobial%20resistance%20genes.PNG%20infants%20experience%20dense%20and%20diverse%20pneumococcal%20colonisation%20with%20concurrent%20serotypes%20from%201%20month%20of%20age.%20PCV13%20had%20no%20impact%20on%20pneumococcal%20carriage%20density%2C%20even%20for%20vaccine%20serotypes.%20The%20low%20prevalence%20of%20vaccine%20serotypes%2C%20high%20pneumococcal%20carriage%20density%20and%20abundance%20of%20non-vaccine%20serotypes%20likely%20contribute%20to%20the%20lack%20of%20PCV13%20impact%20on%20carriage%20in%20PNG%20infants.%20Indirect%20effects%20of%20the%20infant%20PCV%20programs%20are%20likely%20to%20be%20limited%20in%20PNG.%20Alternative%20vaccines%20with%20broader%20coverage%20should%20be%20considered.%22){kind=link}